{"entity":{"id":"stamp-merkel","kind":"trial","name":"STAMP (EA6174)","aka":["STAMP","ECOG-ACRIN EA6174"],"tldr":"STAMP asks whether a year of pembrolizumab after surgery for Merkel cell carcinoma, a skin cancer that often comes back, prevents recurrence; it is one of two randomised trials testing adjuvant immunotherapy in this disease.","summary":"Merkel cell carcinoma recurs in a large share of patients after surgery and radiotherapy, and PD-1 blockade is highly active in advanced disease. STAMP is an ECOG-ACRIN phase 3 trial randomising 280 patients with completely resected stage I to III Merkel cell carcinoma to pembrolizumab every three or six weeks for one year or to observation, with radiotherapy permitted in both arms. The primary endpoint is recurrence-free survival.\n\nThe trial is ongoing and has not reported. The German ADMEC-O trial of adjuvant nivolumab reported a recurrence-free survival advantage in 2023, and STAMP is the larger confirmatory test of the approach.","status":"active","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03712605","url":"https://clinicaltrials.gov/study/NCT03712605"}],"tags":["subtype-trials"],"related":[],"cancers":["merkel-cell-carcinoma","skin-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":["ecog-acrin"],"institutions":[],"pathways":[],"terms":[],"trials":["admec-o","pod1um-201"],"people":["shailender-bhatia"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03712605","phase":"3","setting":"Resected stage I to III Merkel cell carcinoma: one year of adjuvant pembrolizumab against observation","sponsor":"ECOG-ACRIN (National Cancer Institute)","started":"2018-11-15","startedType":"actual","enrolled":280,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/stamp-merkel/","neighbours":{"cancer":[{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","route":"/companies/ecog-acrin/"}],"trial":[{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/"},{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/"}],"person":[{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/"}]}}